Navigation Links
Blunders in Epilepsy Care Cost Lives, and Money UK Report

Incompetent epilepsy care is taking a heavy toll in England, both in terms of lives and money nearly 400 lives and 189m every year , according to a report published today by the All Party Parliamentary Group (APPG) on Epilepsy.

The report - Wasted Money, Wasted Lives - concludes that, despite effective treatments, there are 365 avoidable deaths a year from epilepsy, 69,000 people are living with unnecessary seizures, and 74,000 people are taking anti-epilepsy drugs they do not need.

Baroness Gould, chair of the APPG, says the report identifies a national scandal: "Perhaps the most shocking aspect of the report is the fact that better services would result in savings for the NHS ... and around 189m could be saved every year. This would more than cover the cost of improved services."

Supported by the Joint Epilepsy Council of the UK and Ireland (JEC), the report also condemns what it calls the continued government failure to meet the needs of people living with the condition. "Government guidelines for major changes to the treatment of epilepsy do exist," says Karen Deacon, chair of the JEC.

"But, without targets or powers, these are little more than wish lists and are of little use to patients facing critical service failures." The JEC says the government should accept responsibility for the shortfall in services and increase the numbers of doctors and nurses specializing in epilepsy as a "matter of urgency".

The panel called for greater awareness of Sudden Unexpected Death in Epilepsy, responsible for two-thirds of epilepsy deaths and a particular risk for those who have either not been diagnosed, or whose medication is not effectively controlling their seizures.

"The report's recommendations will simply lift the levels of epilepsy services to match those provided for other long-term conditions," Gould says. "This calls for action at a national level, rather than shifting the blame down to loca
'"/>




Page: 1 2

Related medicine news :

1. Epidural Mistakes Proves To Be Fatal Blunders
2. 36 Patients Die due to Hospital Medication Blunders
3. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Epilepsy can be predicted
6. Epilepsy Drugs Can Enhance Risk of Birth Defects
7. Epilepsy Drug Helps Diabetic Nerve Damage
8. Epilepsy Drug May Relieve Chronic Headaches
9. More Complications Seen In Women With Epilepsy
10. Epilepsy Drugs Found To Lead To Bone Loss
11. Another Use For Epilepsy Drugs
Post Your Comments:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sundia MediTech Appoints Dr Chen Chen as Senior VP of Chemistry 50700 1Sundia MediTech Appoints Dr Chen Chen as Senior VP of Chemistry 50700 2Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 1Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 2Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 3Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 4Dr Julian Whitaker Featured on Searchjointpain com 50694 1Dr Julian Whitaker Featured on Searchjointpain com 50694 2